Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00848926 · ClinicalTrials.gov registry record · Phase 2
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Phase 2 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT00848926 is a Phase 2 study that has completed, run by Seagen. The registered enrollment target is 102 participants.
The verdict
NCT00848926, a Phase 2 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.
Interventions
- DRUG brentuximab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00848926
The ClinicalTrials.gov registry entry for NCT00848926 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which brentuximab vedotin is the first listed.
NCT00848926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00848926 about?
NCT00848926 is a clinical study titled "A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma". This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.
What is the current status of trial NCT00848926?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2009-02. Estimated completion is 2015-05.
What interventions are being tested in trial NCT00848926?
The interventions under investigation include: brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT00848926?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.